Chinese shingles vaccine receives clinical trial approval from Philippines FDA


news desk Lord, save her

Chinese Vaccine Corporation, Jiangsu Recbio Technology Ltd., has received clinical trial approval for a new recombinant shingles vaccine, REC610, from Food and Drug Administration of the Philippines.


The study will evaluate the safety and immunogenicity of REC610 in healthy adults aged 40 and over.

Shingles is an acute contagious skin disease caused by reactivation of the latent varicella zoster virus (VZV) in the body. There is no specific medication for shingles, and the vaccine is an effective way to prevent herpes zoster. According to research data on herpes zoster vaccines that have been marketed worldwide, the new adjuvant vaccine can provide stronger cellular immunity and protective efficacy compared to live attenuated vaccines.

REC610 is equipped with a new BFA01 auxiliary material independently developed by the company, which can enhance the production of

High levels of VZV glycoprotein E (gE) specific CD4+ T cells and antibodies. Preclinical studies have shown that REC610 has favorable immunogenicity and can induce high levels of gE-specific CD4+ T-cell responses and IgG antibody, and its immune response is not inferior to the Shingrix® controlled vaccine.

Leave A Reply

Your email address will not be published.